Insight

Apr 3, 2024, 13:35

Kefah Mokbel: Insights into the management of Leptomeningeal Disease and clinical outcomes

Kefah Mokbel, Chair of The Multidisciplinary Breast Cancer Program at London Breast Institute, shared on LinkedIn:

“Insights into the management of Leptomeningeal disease (LMD) and clinical outcomes:

I would like to add the following comments:

In ER-positive breast cancer, Abemaciclib should be considered the CDK4/6 inhibitor of choice due to its superior penetration through the blood-brain barrier (BBB).

Intrathecal therapy remains underutilized in both research and clinical management settings.

Lumbar puncture for direct genomics analysis is also underutilized and warrants further exploration.

The role of PD-1 and PD-L1 inhibitors in patients with PD-L1 positive disease deserves further discussion (response rates exceeds 30%).”

Proceed to the article.
Source: Kefah Mokbel/LinkedIn

Abemaciclib cancer CDK4/6 inhibitors ER+ breast cancer Kefah Mokbel Leptomeningeal Disease LMD London Breast Institute OncoDaily Oncology PD-1 inhibitors PD-L1 inhibitors

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage